Business
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of FILSPARI and its impact on B cell and complement pathways in IgAN SAN
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"\nNew data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of FILSPARI and its impact on B cell and complement pathways in IgAN\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nTravere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte Conference in Hamburg, Germany, June 10-13, 2025.\n\n\nThe Company will present new data evaluating biomarkers of disease progression in IgA nephropathy (IgAN) from the Phase 2 SPARTAN Study showing rapid and sustained reductions in urinary BAFF and sC5b9 as well as reductions in proinflammatory and profibrotic biomarkers after starting FILSPARI, suggesting disease-modifying activity.\n\n\n“At the International Podocyte conference, we’re pleased to present new biomarker data from the SPARTAN Study that further support the kidney targeted benefit of FILSPARI in the clinical setting,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. “Together with the broader body of existing nonclinical data on FILSPARI, these findings suggest the potential for disease-modifying effects in IgA nephropathy.”\n\n\nInternational Podocyte Conference Presentations\n\n\nUrinary Biomarker Analysis Reveals Rapid Intrarenal Anti-inflammatory and Antifibrotic Effects of Sparsentan in IgA nephropathy in the SPARTAN study\n\n\nPoster #: FR_11\nDate: Friday, 13 June\nLocation: Kleiner Festsaal\nTime: 10:30-11:15; 12:45-14:00 CEST\n\n\nPatients with Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often with Sparsentan vs. Irbesartan in the DUPLEX Study\n\n\nPoster #: FR_26\nDate: Friday, 13 June\nLocation: Small banquet hall\nTime: 10:30-11:15; 12:45-14:00 CEST\n\n\nSparsentan Has Direct Effects on the Glomerular Capillary Wall to Attenuate Increased Permeability in Nephrotic Syndrome Models\n\n\nPoster #: FR_17\nDate: Friday, 13 June\nLocation: Kleiner Festsaal\nTime: 10:30-11:15; 12:45-14:00 CEST\n\n\nAbout IgA Nephropathy\n\n\nIgA nephropathy (IgAN), also called Berger's disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of the normal filtering mechanisms...